Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjectsJacob Lalezari, Joseph Gathe, Cynthia Brinson, et al.HIV Clinical Trials|August 30, 2008
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once dailyRichard Elion, Calvin Cohen, Douglas Ward, et al.Antimicrobial Agents and Chemotherapy|August 20, 2008
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scoresPhilip Grant, Eric C Wong, Richard Rode, et al.Frontiers in Immunology|November 25, 2022
Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling studySergio Serrano-Villar, Calvin Cohen, Jason V Baker, et al.Frontiers in Immunology|March 6, 2023
Corrigendum: Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling studySergio Serrano-Villar, Calvin Cohen, Jason V Baker, et al.AIDS (London, England)|August 4, 2011
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionRichard Elion, Calvin Cohen, Joseph Gathe, et al.AIDS Research and Human Retroviruses|July 1, 2009
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)Lisa Ross, Richard Elion, Randall Lanier, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 11, 2007
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3Jean-Michel Molina, Calvin Cohen, Christine Katlama, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2006
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsEdwin DeJesus, Daniel Berger, Martin Markowitz, et al.HIV Clinical Trials|October 23, 2013
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimensAnthony M Mills, Calvin Cohen, Edwin Dejesus, et al.Pageof 4